Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression

Cancer. 2005 Mar 15;103(6):1186-94. doi: 10.1002/cncr.20905.


Background: Over-expression of the oncogene c-Myc has been implicated in the development and progression of human prostate carcinoma. However, previous assessments of c-Myc expression have not revealed its potential for predicting prostate carcinoma progression. Caveolin-1 is associated with prostate carcinoma progression and is a downstream target gene of c-Myc. The observation that caveolin-1 can suppress c-Myc-induced apoptosis suggested the potential for cooperation between c-Myc and caveolin-1 in malignant progression. In this study, the authors evaluated the prognostic potential of combined c-Myc and caveolin-1 expression in human prostate carcinoma progression.

Methods: Immunostaining with c-Myc and caveolin-1-specific antibodies was performed on paraffin sections from 104 radical prostatectomy specimens from men with lymph node negative prostate carcinoma. Combined c-Myc and caveolin-1 immunostaining scores were related with the clinical and pathologic features and the probability of prostate-specific antigen recurrence after surgery.

Results: The combination of c-Myc and caveolin-1 immunopositivity correlated positively with Gleason score (rho = 0.219; P = 0.0253) and positive surgical margin (rho = 0.333; P = 0.0006). The combination of positive c-Myc and caveolin-1 in patients with clinically confined prostate carcinoma was a significant prognostic marker for the time to disease progression after surgery in both univariate analysis (P = 0.0039; hazard ratio, 3.035) and multivariate analysis (P = 0.0114; hazard ratio, 2.916).

Conclusions: The coexpression of c-Myc and caveolin-1 showed potential as a useful prognostic marker for human prostate carcinoma. The current results suggest interactions between c-Myc and caveolin-1 in the progression of human prostate carcinoma.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenocarcinoma / pathology*
  • Adenocarcinoma / surgery
  • Age Distribution
  • Aged
  • Biomarkers, Tumor / metabolism*
  • Biopsy, Needle
  • Caveolin 1
  • Caveolins / analysis*
  • Cohort Studies
  • Confidence Intervals
  • Disease Progression
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Probability
  • Prognosis
  • Proportional Hazards Models
  • Prostatectomy / methods
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / pathology*
  • Prostatic Neoplasms / surgery
  • Proto-Oncogene Proteins c-myc / metabolism*
  • Risk Assessment
  • Sensitivity and Specificity
  • Survival Analysis
  • Tissue Culture Techniques
  • Treatment Outcome


  • Biomarkers, Tumor
  • CAV1 protein, human
  • Caveolin 1
  • Caveolins
  • Proto-Oncogene Proteins c-myc